NDAORALCAPSULE
Approved
Dec 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
LINCOCIN (lincomycin hydrochloride) by Pfizer is mechanism of action lincomycin inhibits bacterial protein synthesis by binding to the 23s rna of the 50s subunit of the bacterial ribosome. Approved for the treatment of serious infections due to susceptible strains of streptococci, pneumococci, staphylococci and 2 more indications. First approved in 1964.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LINCOCIN (lincomycin hydrochloride) is an oral antibiotic capsule approved in 1964 that treats serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci. It works by inhibiting bacterial protein synthesis through binding to the 23S RNA of the 50S ribosomal subunit, functioning as a bacteriostatic agent. The drug also addresses minor bacterial and viral infections.
$0.95MPart D
LOE ApproachingDeclining
Declining Part D spending and minimal claims signal a mature product in decline; expect small, focused teams managing legacy revenue.
Mechanism of Action
Mechanism of Action Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro .
Worked on LINCOCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.